Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II basket study of Debio 1347 in FGFR1-3 fusion solid tumors
2018-003584-53Phase 2Completed
- Sponsor
- Debiopharm
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zoligratinib in biliary cancer, transitional cell carcinoma (TCC), non-small cell lung cancer (NSCLC) and 6 more, sponsored by Debiopharm. Primary endpoint: Objective response rate (ORR). Started Dec 2018; status: completed.
02
Drugs
zoligratinib
03
Conditions
biliary cancertransitional cell carcinoma (TCC)non-small cell lung cancer (NSCLC)head and neck cancer (HNC)thyroid cancer
Beyond the preview
Go deeper on 2018-003584-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003584-53.